Other analysts have also recently issued research reports about the company. Oppenheimer assumed coverage on Crispr Therapeutics in a research report on Monday, July 27th. They set a "buy" rating and a $105.00 price target for the company. Citigroup reaffirmed a "sell" rating on shares of Crispr Therapeutics in a research report on Wednesday, August 5th. Wells Fargo & Co lifted their price target on Crispr Therapeutics from $95.00 to $110.00 and gave the stock an "overweight" rating in a research report on Tuesday, July 28th. William Blair reaffirmed a "buy" rating on shares of Crispr Therapeutics in a research report on Tuesday, July 28th. Finally, Piper Sandler reissued an "overweight" rating and issued a $104.00 price objective on shares of Crispr Therapeutics in a report on Friday, June 19th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and twelve have given a buy rating to the company. Crispr Therapeutics currently has a consensus rating of "Buy" and an average target price of $90.93.
Crispr Therapeutics stock opened at $93.42 on Wednesday. The stock has a market capitalization of $6.37 billion, a price-to-earnings ratio of 203.09 and a beta of 2.35. Crispr Therapeutics has a 1-year low of $32.30 and a 1-year high of $105.12. The business has a fifty day moving average price of $90.56 and a 200-day moving average price of $65.14.
Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Monday, July 27th. The company reported ($1.30) EPS for the quarter, missing the Zacks' consensus estimate of ($0.95) by ($0.35). Crispr Therapeutics had a return on equity of 2.35% and a net margin of 6.77%. The firm had revenue of $0.04 million for the quarter, compared to analyst estimates of $19.77 million. During the same period in the prior year, the firm posted ($1.01) EPS. The business's revenue was down 86.2% compared to the same quarter last year. As a group, equities research analysts forecast that Crispr Therapeutics will post -4.74 EPS for the current year.
In related news, VP Tony W. Ho sold 7,158 shares of Crispr Therapeutics stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $75.04, for a total value of $537,136.32. Following the completion of the transaction, the vice president now owns 40,676 shares in the company, valued at approximately $3,052,327.04. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Bradley J. Phd Bolzon sold 20,000 shares of Crispr Therapeutics stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $73.93, for a total value of $1,478,600.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 187,246 shares of company stock valued at $14,605,668. 17.10% of the stock is owned by company insiders.
A number of large investors have recently bought and sold shares of CRSP. Nikko Asset Management Americas Inc. increased its stake in Crispr Therapeutics by 23.5% during the 1st quarter. Nikko Asset Management Americas Inc. now owns 3,766,541 shares of the company's stock worth $159,739,000 after buying an additional 716,988 shares in the last quarter. Morgan Stanley increased its stake in Crispr Therapeutics by 233.6% during the 1st quarter. Morgan Stanley now owns 851,519 shares of the company's stock worth $36,113,000 after buying an additional 596,255 shares in the last quarter. TimesSquare Capital Management LLC purchased a new stake in Crispr Therapeutics during the 1st quarter worth approximately $15,410,000. Avidity Partners Management LP purchased a new stake in Crispr Therapeutics during the 2nd quarter worth approximately $20,158,000. Finally, Casdin Capital LLC purchased a new stake in Crispr Therapeutics during the 1st quarter worth approximately $11,299,000. Institutional investors own 55.29% of the company's stock.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
See Also: Outstanding Shares
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]